Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Leukemia |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 10/26/2018 |
| Start Date: | May 16, 2013 |
| End Date: | July 2020 |
| Contact: | Brandon M. Triplett, MD |
| Email: | referralinfo@stjude.org |
| Phone: | 866-278-5833 |
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic
cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA) matched
related/sibling donor (MSD) or matched unrelated donor (MUD) identified, will receive a
haploidentical donor HCT with additional natural killer (NK) cells.
The investigators anticipate enrollment of 75 donors and 75 recipients.
PRIMARY OBJECTIVE:
- To estimate the rate of successful engraftment at day +42 post-transplant in patients
who receive haploidentical donor stem cell plus NK cell transplantation with TLI based
conditioning regimen for high risk hematologic malignancy.
SECONDARY OBJECTIVES:
- Estimate the incidence of malignant relapse, event-free survival, and overall survival
at one-year post-transplantation.
- Estimate incidence and severity of acute and chronic (GVHD).
- Estimate the rate of transplant related mortality (TRM) in the first 100 days after
transplantation.
cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA) matched
related/sibling donor (MSD) or matched unrelated donor (MUD) identified, will receive a
haploidentical donor HCT with additional natural killer (NK) cells.
The investigators anticipate enrollment of 75 donors and 75 recipients.
PRIMARY OBJECTIVE:
- To estimate the rate of successful engraftment at day +42 post-transplant in patients
who receive haploidentical donor stem cell plus NK cell transplantation with TLI based
conditioning regimen for high risk hematologic malignancy.
SECONDARY OBJECTIVES:
- Estimate the incidence of malignant relapse, event-free survival, and overall survival
at one-year post-transplantation.
- Estimate incidence and severity of acute and chronic (GVHD).
- Estimate the rate of transplant related mortality (TRM) in the first 100 days after
transplantation.
Donors will undergo G-CSF mobilization of peripheral blood stem cells (PBSC) prior to
undergoing two apheresis collections of hematopoietic progenitor cells (HPC,A) and one
apheresis collection of therapeutic cell product of purified natural killer cells (TC-NK).
The HPC products will be T-cell depleted (TCD) using the investigational CliniMACS device.
CD34+ enrichment and CD45RA depletion will be utilized on sequential HPC grafts.
Participants will undergo a preparative regimen of total lymphoid irradiation, fludarabine,
cyclophosphamide, granulocyte colony stimulating factor (G-CSF), thiotepa, and melphalan.
This is followed by infusions of donor cells that have been prepared using the CliniMACS
system: HPC,A (CD34+ selected), HPC,A (CD45RA depleted), and TC-NK.
undergoing two apheresis collections of hematopoietic progenitor cells (HPC,A) and one
apheresis collection of therapeutic cell product of purified natural killer cells (TC-NK).
The HPC products will be T-cell depleted (TCD) using the investigational CliniMACS device.
CD34+ enrichment and CD45RA depletion will be utilized on sequential HPC grafts.
Participants will undergo a preparative regimen of total lymphoid irradiation, fludarabine,
cyclophosphamide, granulocyte colony stimulating factor (G-CSF), thiotepa, and melphalan.
This is followed by infusions of donor cells that have been prepared using the CliniMACS
system: HPC,A (CD34+ selected), HPC,A (CD45RA depleted), and TC-NK.
Inclusion Criteria - Transplant Recipients:
- Age less than or equal to 21 years.
- Does not have a suitable MSD or volunteer MUD available in the necessary time for stem
cell donation.
- Has a suitable single haplotype matched (≥ 3 of 6) and family member donor.
- High risk hematologic malignancy.
- If prior CNS leukemia, it must be treated and in CNS CR
- Does not have any other active malignancy other than the one for which this HCT is
indicated.
- No prior allogeneic HCT, and no autologous HCT within the previous 12 months.
- Patient must fulfill pre-transplant evaluation
Inclusion Criteria - Haploidentical Donor:
- At least single haplotype matched (≥ 3 of 6) family member
- At least 18 years of age.
- HIV negative.
- Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days
prior to enrollment (if female).
- Not breast feeding.
- Regarding eligibility, is identified as either: (1) Completed the process of donor
eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR (2) Does
not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical
need completed by the principal investigator or physician sub-investigator per 21 CFR
1271.
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Brandon M. Triplett, MD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
